Article

EDITORS’ NOTE

A New Weapon in the Presbyopia Treatment Armamentarium

A NEW YEAR BRINGS NEW HOPES AND GOALS. AS Phil Collins would say, “I can feel it coming in the air tonight.” We have great reason to embrace the optimism, substantiated by the recent approval and launch of Vuity (Allergan). The FDA approval for the first topical therapy for presbyopia correction opens the floodgates to a mountain of buzz with social posts, news broadcasts, and publications. Among all the chatter between colleagues and the barrage of calls from patients with questions like “Will this work for me?”, the unanswered questions of the 5 Ws are tingling in eye care’s intellect. It reiterates just how important vision is to our patients and to our profession, and it highlights just how problematic presbyopia is perceived to be in the United States.

Answering and treating our patients’ visual problems and inadequacies form the epicenter of what we do. In this issue, we hope to help you find answers to some of the questions you may have about presbyopia in 2022 and beyond. It’s too soon to have seen much with Vuity yet, but we’ve included some thoughts and very early strategies on how it might best be used. Also found here is information about the upcoming small aperture intraocular lens (the IC-8), the MyDay multifocal contact lens, and enhanced depth of focus contact lenses, as well as useful practice management ideas.

We at Presbyopia Physician look forward to helping you answer the questions surrounding this new world of options for presbyopia therapies. Have a happy, healthy, and successful 2022! ■

Chief Co-Editors

Elizabeth Yeu, MD and
Jacob Lang, OD